An interventional study of L-Arginine and placebo in Pre-eclampsia, sponsored by Quaid-e-Azam Medical College. Completed at 1 site in Pakistan. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Quaid-e-Azam Medical College · Not applicable, Interventional, and Prevention
This study was designed to assess whether daily L-arginine supplementation could prevent preeclampsia in pregnant women at increased risk. Preeclampsia, a pregnancy complication involving high blood pressure and possible organ damage, was the condition of interest. The study hypothesis was that L-arginine supplementation would be more effective than placebo in preventing preeclampsia before delivery.
The study was designed as a randomized controlled trial at the Department of Gynaecology and Obstetrics, Bahawal Victoria Hospital, Bahawalpur, Pakistan. Eligible participants were women aged 18-40 years with a single-baby pregnancy at 20 weeks and an increased risk of preeclampsia based on their personal or family medical history. The protocol specified assignment by chance to either daily oral L-arginine supplementation or placebo until delivery.
Follow-up visits were scheduled every three weeks during pregnancy and two weeks after childbirth. Assessments included blood pressure, urine testing for protein, and monitoring for side effects. The main outcome was the proportion of women who remained free of preeclampsia until delivery. Other planned assessments included pregnancy complications, delivery outcomes, birth weight, newborn health, and admission to intensive care.
905 studies on the registry are indexed under Pre-Eclampsia; 238 are open to participants now.
This study's enrollment of 108 is close to the median of 110 across 478 interventional studies indexed under Pre-Eclampsia.
Browse Pre-Eclampsia studies →Quaid-e-Azam Medical College is the lead sponsor of 11 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Received oral L-arginine supplementation once daily after a meal, dissolved in one cup of water, from enrollment at 20 weeks of pregnancy until delivery.
Dietary Supplement: L-Arginine
Received oral placebo once daily from enrollment at 20 weeks of pregnancy until delivery.
Drug: placebo
L-arginine supplementation administered orally once daily after a meal until delivery.
Oral placebo administered once daily until delivery.
Percentage of Participants Who Remained Free of Preeclampsia Until Delivery
Efficacy was measured as the percentage of participants in each study group who did not develop preeclampsia before delivery. According to the synopsis, preeclampsia was defined as new-onset systolic blood pressure \>140 mmHg and diastolic blood pressure \>90 mmHg, together with urinary protein excretion \>300 mg over 24 hours, after 20 weeks of gestation in previously normotensive women.
Time frame: From enrollment at 20 weeks of gestation until delivery,
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Arginine
Quaid-e-Azam Medical College